In TCGA-BRCA and TCGA-PRAD patient datasets, both CCL22 and TNFSF10 expression were positively correlated with tumor infiltration of some immune cell types (Fig. 4A). This evidence concerns the gene CCL22 and invasive breast carcinoma.